NEW YORK (360Dx) – Oncimmune Holdings said today that it has obtained the CE mark for its autoantibody, blood-based EarlyCDT-Lung test in an ELISA kit format.

The test can detect lung cancer up to four years earlier than other methods, the firm said, adding that it will now be made available "to hospitals around the world for running in their own laboratories."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.